The diagnostic performance of non-invasive fibrosis markers for predicting fibrosis in primary biliary cholangitis patients

Bu makale geri çekilmiştir. https://dergipark.org.tr/tr/pub/tjcl/article/1594235

Geri Çekme Notu

Yazarlar arasında oluşan çıkar çatışması nedeniyle sorumlu yazar tarafından makelenin geri çekilmesi talep edilmiş ve editör kurulu tarafından yazarlardan çıkar çatışmasına yönelik savunma talep edilmiştir. Editör kurulu tarafından yazarlar arasındak çıkar çatışması değerlendirilmiş ve sorumlu yazar tarafından talep edilen makelenin geri çekilmesi uygun bulunmuştur.

Öz

Aim: This study aimed to investigate the relationship between liver fibrosis measured by transient elastography and non-invasive fibrosis scoring systems, including Fibrosis-4 (FIB-4) and aspartate-aminotransferase (AST)-to-platelet ratio index (APRI), in patients with primary biliary cholangitis (PBC). Material and Methods: A total of 45 PBC patients followed in the Gastroenterology Clinic were included in this retrospective study. Transient elastography was performed on all participants, and liver stiffness measurement (LSM) values were recorded in kilopascals (kPa). Fibrosis was defined as LSM ≥ 6.3 kPa, while advanced fibrosis was defined as LSM ≥ 10.5 kPa. To calculate the APRI score, the formula [(AST / upper normal limit × 100) / platelet count] was used, and for the FIB-4 score, the formula [(age × AST) / (platelet count × √alanine aminotransferase)] was applied. Results: Liver fibrosis was identified in 71.1% (n = 32) of patients, with advanced fibrosis present in 40.0% (n = 18). Patients with fibrosis had higher APRI and FIB-4 scores compared to those without fibrosis. Also, the median APRI score (0.7 vs. 0.5, p < 0.001) and median FIB-4 score (2.4 vs. 1.6, p < 0.001) were higher in patients with advanced liver fibrosis than in those without. For detecting fibrosis, the AUROC values were 0.73 (95% CI: 0.58–0.89) for APRI and 0.84 (95% CI: 0.73–0.96) for FIB-4. FIB-4 also showed higher accuracy than APRI for identifying advanced fibrosis (AUROC: 0.78 vs. 0.70, p = 0.042). Conclusion: Both APRI and FIB-4 are useful non-invasive tools for detecting and staging fibrosis in PBC. However, FIB-4 demonstrated superior diagnostic performance compared to APRI, particularly in predicting advanced fibrosis. Incorporating these markers into routine clinical practice may reduce the need for invasive liver biopsy and help optimize patient management.

Anahtar Kelimeler

• Primary biliary cholangitis
• transient elastography
• liver fibrosis
• FIB-4 score
• APRI score

Primer biliyer kolanjit hastalarında fibrozisi öngörmede invaziv olmayan fibrozis belirteçlerinin tanısal performansı

Bu makale geri çekilmiştir. https://dergipark.org.tr/tr/pub/tjcl/article/1594235

Öz

Amaç: Bu çalışma, primer biliyer kolanjit (PBC) hastalarında transient elastografi ile ölçülen karaciğer fibrozisi ile Fibrozis-4 (FIB-4) ve aspartat-aminotransferaz-trombosit oranı indeksi (APRI) gibi non-invaziv fibrozis skorlama sistemleri arasındaki ilişkiyi araştırmayı amaçladı. Gereç ve Yöntemler: Gastroenteroloji Kliniği’nde takip edilen toplam 45 PBC hastası bu retrospektif çalışmaya dahil edildi. Tüm katılımcılara transient elastografi uygulandı ve karaciğer sertliği ölçüm (LSM) değerleri kilopaskal (kPa) cinsinden kaydedildi. Fibrozis, LSM ≥ 6.3 kPa olarak tanımlanırken, ileri fibrozis LSM ≥ 10.5 kPa olarak kabul edildi. APRI skorunun hesaplanmasında [(AST / üst normal sınır × 100) / trombosit sayısı] formülü, FIB-4 skorunun hesaplanmasında ise [(yaş × AST) / (trombosit sayısı × √alanin aminotransferaz)] formülü uygulandı. Bulgular: Hastaların %71.1’inde (n = 32) karaciğer fibrozisi, %40.0’ında (n = 18) ise ileri fibrozis saptandı. Fibrozisi olan hastalarda ibrozisi olmayan hastalara kıyasla APRI ve FIB-4 skorları f daha yüksekti. İleri fibrozisi olan hastalarda ileri fibrozis olmayan hastalara kıyasla da APRI (0.7 vs. 0.5, p < 0.001) ve FIB-4 (2.4 vs. 1.6, p < 0.001) skorları daha yüksekti. Fibrozisin saptanmasında, AUROC değerleri APRI için 0.73 (%95 GA: 0.58–0.89) ve FIB-4 için 0.84 (%95 GA: 0.73–0.96) olarak bulundu. FIB-4, ileri fibrozisi belirlemede de APRI’ye göre daha yüksek doğruluk gösterdi (AUROC: 0.78 karşı 0.70, p = 0.042). Sonuç: APRI ve FIB-4, PBC hastalarında fibrozis tespiti ve evrelemesi için kullanışlı non-invaziv araçlardır. Bununla birlikte, FIB-4 özellikle ileri fibrozisi öngörmede APRI’ye kıyasla üstün tanısal performans sergilemiştir. Bu belirteçlerin rutin klinik uygulamalara dahil edilmesi, invaziv karaciğer biyopsisi ihtiyacını azaltabilir ve hasta yönetimini optimize etmeye yardımcı olabilir.

Anahtar Kelimeler

• Primer biliyer kolanjit
• transient elastografi
• karaciğer fibrozisi
• FIB-4 skoru
• APRI skoru

Kaynakça

1. Parés A. Primary biliary cholangitis. Medicina Clínica (English Edition). 2018;151(6):242-49.
2. Tanaka A. Current understanding of primary biliary cholangitis. Clin Mol Hepatol. 2021;27(1):1-21.
3. Lleo A, Marzorati S, Anaya J-M, and Gershwin ME. Primary biliary cholangitis: a comprehensive overview. Hepatology international. 2017;11:485-99.
4. Juran BD and Lazaridis KN. Environmental factors in primary biliary cirrhosis. Semin Liver Dis. 2014;34(3):265-72.
5. McGee EE, Castro FA, Engels EA, et al. Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults. Int J Cancer. 2019;144(4):707-17.
6. Pares A, Albillos A, Andrade RJ, et al. Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. Rev Esp Enferm Dig. 2018;110(10):641-49.
7. Isayama H, Tazuma S, Kokudo N, et al. Clinical guidelines for primary sclerosing cholangitis 2017. J Gastroenterol. 2018;53(9):1006-34.
8. Lindor KD, Bowlus CL, Boyer J, Levy C, and Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394-419.

9. Wu L, Ding J, Zhang N-P, Li F, Liu X-P, and Wu J. Mechanisms of Fibrosis in Primary Biliary Cholangitis. Current Hepatology Reports. 2020;19:96-105.
10. Barrault C, Roudot-Thoraval F, Van Nhieu JT, et al. Non-invasive assessment of liver graft fibrosis by transient elastography after liver transplantation. Clinics and research in hepatology and gastroenterology. 2013;37(4):347-52.
11. Lutz H, Schroeter B, Kroy D, Neumann U, Trautwein C, and Tischendorf J. Doppler ultrasound and transient elastography in liver transplant patients for noninvasive evaluation of liver fibrosis in comparison with histology: a prospective observational study. Digestive diseases and sciences. 2015;60:2825-31.
12. Vergniol J, Boursier J, Coutzac C, et al. Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C. Hepatology. 2014;60(1):65-76.
13. Masuzaki R, Yamashiki N, Sugawara Y, et al. Assessment of liver stiffness in patients after living donor liver transplantation by transient elastography. Scandinavian journal of gastroenterology. 2009;44(9):1115-20.
14. Rabindranath M, Zaya R, Prayitno K, et al. A Comprehensive Review of Liver Allograft Fibrosis and Steatosis: From Cause to Diagnosis. Transplantation Direct. 2023;9(11):e1547.
15. Avcioglu U, Eruzun H, and Ustaoglu M. The gamma-glutamyl transferase to platelet ratio for noninvasive evaluation of liver fibrosis in patients with primary biliary cholangitis. Medicine (Baltimore). 2022;101(40):e30626.
16. Sayar S, Gokcen P, Aykut H, Adali G, Doganay HL, and Ozdil K. Can simple Non-Invasive Fibrosis Models Determine Prognostic Indicators (Fibrosis and Treatment Response) of Primary Biliary Cholangitis? Sisli Etfal Hastan Tip Bul. 2021;55(3):412-18.
17. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-25.
18. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase‐to‐platelet ratio index for the staging of hepatitis C‐related fibrosis: an updated meta‐analysis. Hepatology. 2011;53(3):726-36.
19. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-54.
20. Siddiqui MS, Idowu MO, Stromberg K, et al. Diagnostic performance of vibration-controlled transient elastography in liver transplant recipients. Clinical Gastroenterology and Hepatology. 2021;19(2):367-74.
21. Sun Y, Haapanen K, Li B, Zhang W, Van de Water J, and Gershwin ME. Women and primary biliary cirrhosis. Clin Rev Allergy Immunol. 2015;48(2-3):285-300.
22. Floreani A, Gabbia D, and De Martin S. Are Gender Differences Important for Autoimmune Liver Diseases? Life (Basel). 2024;14(4):500.
23. Bidiuk J, Szmigielski C, Lewandowski J, and Sinski M. Cardiac morphology and function in patients with primary biliary cholangitis (PBC) without cirrhosis. European Heart Journal. 2024;45(Supplement_1):ehae666. 3039.
24. Gangireddy VG, Kanneganti PC, Sridhar S, Talla S, and Coleman T. Management of thrombocytopenia in advanced liver disease. Can J Gastroenterol Hepatol. 2014;28(10):558-64.
25. Kalas MA, Chavez L, Leon M, Taweesedt PT, and Surani S. Abnormal liver enzymes: A review for clinicians. World J Hepatol. 2021;13(11):1688-98.
26. Corpechot C, Carrat F, Poujol-Robert A, et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology. 2012;56(1):198-208.
27. Poupon R. Non-Invasive Assessment of Liver Fibrosis Progression and Prognosis in Primary Biliary Cholangitis. Dig Dis. 2015;33 Suppl 2:115-7.
28. Li Y, Zhang MJ, Wang XH, and Li SH. Novel noninvasive indices for the assessment of liver fibrosis in primary biliary cholangitis. Biomed Rep. 2024;20(1):1.
29. Olmez S, Sayar S, Avcioglu U, et al. The relationship between liver histology and noninvasive markers in primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 2016;28(7):773-6.